Registry of IgA Nephropathy in Chinese Children

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Jan 6, 2017

Keywords

ClinConnect Summary

This clinical trial is focused on finding safe and effective treatments for a kidney condition called IgA nephropathy in children. The study will involve 25 hospitals across China and aims to help doctors understand how to best manage this condition, especially when children have a high level of protein in their urine, which can indicate kidney problems. The trial is currently looking for participants, specifically children diagnosed with primary IgA nephropathy who show signs of nephrotic syndrome, meaning they have a significant amount of protein in their urine.

To be eligible for this study, children must have a confirmed diagnosis of IgA nephropathy and meet certain criteria related to their urine protein levels. Before participating, parents or guardians will need to provide informed consent, which means they will be fully informed about the study and agree to take part. If your child is diagnosed with IgA nephropathy and fits these criteria, they may have the opportunity to participate in this important research, contributing to a better understanding of how to treat this condition in the future.

Gender

ALL

Eligibility criteria

• • In-patients will be enrolled with the following criteria.
• Inclusion Criteria:
• • Clinical diagnosis of primary IgA nephropathy.
• • Presenting with nephrotic proteinuria, defined as 24-hour urinary protein\>50mg/kg, or UPC\>2.0 mg/mg.
• • Informed consent must be signed.
• Exclusion Criteria:
• • Diagnosed as secondary renal diseases, including lupus nephritis, purpura nephritis, hepatitis B virus associated nephritis, etc.

Trial Officials